Targeting the PlsX/Y pathway for novel antimicrobials
靶向 PlsX/Y 途径的新型抗菌药物
基本信息
- 批准号:7916838
- 负责人:
- 金额:$ 53.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-19 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAcyltransferaseAdverse effectsAffectAlternative TherapiesAmidesAnabolismAnthrax diseaseAnti-Bacterial AgentsAntibiotic ProphylaxisAntibioticsAreaB-LymphocytesBacillus anthracisBacteriaBiochemistryBiologicalBiological AssayBiological AvailabilityBioterrorismCharacteristicsCiprofloxacinDataDevelopmentDiseaseDrug DesignDrug KineticsEngineeringEnsureEnzymesEvaluationEventFeedbackFluoroquinolonesFutureGenesGenomeGerminationGlycerolGram-Positive BacteriaGrantHomologous GeneIn VitroLeadLipid BiochemistryMediatingMembraneMetabolicMetabolismMicrobiologyOralPathway interactionsPenetrationPeptide HydrolasesPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPhospholipidsPopulationProdrugsProductionPropertyProphylactic treatmentProteinsReproduction sporesResearch PersonnelResistanceScreening procedureSeriesSolubilityStreptococcus pneumoniaeSulfonylurea CompoundsTestingVaccinesVirulentWorkaerosolizedanalogantimicrobialantimicrobial drugbasecellular targetingcytotoxicitydesigndrug discoveryin vivoinhibitor/antagonistinorganic phosphatelipid metabolismmutantnovelpathogenphosphonate
项目摘要
In an effort to develop new targets for antibacterial drug discovery, we recently discovered that Gram positive bacteria use a unique and essential pathway to synthesize their membrane phospholipids mediated by two gene products, PlsX and PlsY. This pathway generates a unique acyl-phosphate intermediate via PlsX that is then utilized as a substrate for PlsY. PlsY is an essential acyltransferase and there are no mammalian homologs. Using a bioisosteric approach we designed a number of nonhydrolyzable mimics of the acyl-phosphate intermediate. When tested against a panel of representative gram positive pathogens these compounds showed only modest antimicrobial activity, with the exception of B. anthracis (Sterne strain) that was potently inhibited. To confirm this result we then tested these compounds against a panel of virulent B. anthracis strains, all of which were highly sensitive to our best inhibitors yielding comparable MIC activity to existing antibiotics. We believe that this is an ideal starting point for the development of selective B. anthracis inhibitors, which will be explored in this grant. This study has 3 specific aims: (i) To synthesize an expanded set of inhibitors and to optimize the lead compounds with respect to anti-anthracis activity and for potential oral bioavailability; (ii) to biochemically evaluate the inhibition of the B. anthracis PlsY enzymes by the newly synthesized inhibitors; (iii) To perform a microbiological assessment on the emerging lead compounds, including testing for anti-B. anthracis activity. The end point of our studies will produce a better understanding of this important biological pathway and determine whether it is a suitable target for antibacterial drug discovery.
为了开发抗菌药物发现的新靶标,我们最近发现革兰氏阳性细菌使用独特且重要的途径来合成由两种基因产物 PlsX 和 PlsY 介导的膜磷脂。该途径通过 PlsX 生成独特的酰基磷酸中间体,然后将其用作 PlsY 的底物。 PlsY 是一种必需的酰基转移酶,没有哺乳动物同源物。使用生物等排方法,我们设计了许多不可水解的酰基磷酸中间体的模拟物。当针对一组代表性革兰氏阳性病原体进行测试时,这些化合物仅表现出适度的抗菌活性,但炭疽芽孢杆菌(斯特恩菌株)除外,其被有效抑制。为了证实这一结果,我们随后针对一组剧毒炭疽芽孢杆菌菌株测试了这些化合物,所有这些菌株都对我们最好的抑制剂高度敏感,产生与现有抗生素相当的 MIC 活性。我们相信,这是开发选择性炭疽杆菌抑制剂的理想起点,本次拨款将对此进行探索。这项研究有 3 个具体目标:(i) 合成一组扩展的抑制剂,并优化先导化合物的抗炭疽活性和潜在的口服生物利用度; (ii)通过生化评估新合成的抑制剂对炭疽芽孢杆菌PlsY酶的抑制作用; (iii) 对新出现的先导化合物进行微生物学评估,包括抗 B 菌测试。炭疽活动。我们研究的终点将有助于更好地理解这一重要的生物学途径,并确定它是否是抗菌药物发现的合适靶点。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening.
通过虚拟筛选发现新型细菌延伸缩合酶抑制剂。
- DOI:
- 发表时间:2014-06-01
- 期刊:
- 影响因子:2.7
- 作者:Zheng, Zhong;Parsons, Joshua B;Tangallapally, Rajendra;Zhang, Weixing;Rock, Charles O;Lee, Richard E
- 通讯作者:Lee, Richard E
Acyl-sulfamates target the essential glycerol-phosphate acyltransferase (PlsY) in Gram-positive bacteria.
酰基氨基磺酸盐靶向革兰氏阳性菌中必需的磷酸甘油酰基转移酶 (PlsY)。
- DOI:10.1016/j.bmc.2012.06.029
- 发表时间:2012-08-15
- 期刊:
- 影响因子:3.5
- 作者:Cherian PT;Yao J;Leonardi R;Maddox MM;Luna VA;Rock CO;Lee RE
- 通讯作者:Lee RE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard E. Lee其他文献
Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis
异烟肼影响结核分枝杆菌 II 型脂肪酸合酶系统的多个成分
- DOI:
10.1046/j.1365-2958.2000.02145.x - 发表时间:
2000-11-01 - 期刊:
- 影响因子:3.6
- 作者:
R. Slayden;Richard E. Lee;C. Barry - 通讯作者:
C. Barry
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer
Bromodomain 选择性 BET 抑制剂是针对 MYC 驱动的小儿癌症的有效抗肿瘤药物
- DOI:
10.1158/0008-5472.can-19-3934 - 发表时间:
2020-07-10 - 期刊:
- 影响因子:11.2
- 作者:
P. J. Slavish;Liying Chi;M. Yun;Lyudmila S. Tsurkan;Nancy E. Martinez;Barbara Jonchere;S. Chai;M. Connelly;M. B. Waddell;Sourav Das;G. Neale;Zhenmei Li;W. Shadrick;R. Olsen;Kevin Freeman;J. Low;Jeanine E. Price;Br;on M. Young;on;N. Bharatham;Vincent A. Boyd;Jun J. Yang;Richard E. Lee;M. Morfouace;Martine F. Roussel;Taosheng Chen;D. Savic;R. K. Guy;Stephen W. White;A. Shelat;Philip M. Potter - 通讯作者:
Philip M. Potter
The small molecule CBR-5884 inhibits the Candida albicans phosphatidylserine synthase
小分子 CBR-5884 抑制白色念珠菌磷脂酰丝氨酸合酶
- DOI:
10.1128/mbio.00633-24 - 发表时间:
2023-11-01 - 期刊:
- 影响因子:6.4
- 作者:
Yue Zhou;Gregory A Phelps;Mikayla M Mangrum;Jemma McLeish;Elise K. Phillips;Jinchao Lou;Christelle F. Ancajas;J. Rybak;Peter M. Oelkers;Richard E. Lee;Michael D. Best;Todd B. Reynolds - 通讯作者:
Todd B. Reynolds
In Vitro and In Vivo Activities of HPi 1 , a Selective Antimicrobial against Helicobacter pylori
HPi 1(一种针对幽门螺杆菌的选择性抗菌剂)的体外和体内活性
- DOI:
- 发表时间:
2024-09-14 - 期刊:
- 影响因子:0
- 作者:
E. Gavrish;Binu Shrestha;Chao Chen;Ida M Lister;E. J. North;Lei Yang;Richard E. Lee;Angel Han;B. Williams;David Charnuska;K. Coleman;K. Lewis;Michael D. LaFleur - 通讯作者:
Michael D. LaFleur
Brief communication Rapid cold-hardening increases membrane Xuidity and cold tolerance of insect cells !
简短交流 快速冷硬化可提高昆虫细胞膜的吸湿性和耐寒性!
- DOI:
10.35654/ijnhs.v6i5.747 - 发表时间:
2006 - 期刊:
- 影响因子:0
- 作者:
Richard E. Lee;K. Damodaran;S. Yi;G. Lorigan - 通讯作者:
G. Lorigan
Richard E. Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard E. Lee', 18)}}的其他基金
Training in the Design and Development of Infectious Disease Therapeutics
传染病治疗药物设计和开发培训
- 批准号:
10617855 - 财政年份:2015
- 资助金额:
$ 53.95万 - 项目类别:
Training in the Design and Development of Infectious Disease Therapeutics
传染病治疗药物设计和开发培训
- 批准号:
10447715 - 财政年份:2015
- 资助金额:
$ 53.95万 - 项目类别:
Development of Aminospectinomycins for Biodefense
用于生物防御的氨基大观霉素的开发
- 批准号:
9291410 - 财政年份:2014
- 资助金额:
$ 53.95万 - 项目类别:
Development of Aminospectinomycins for Biodefense
用于生物防御的氨基大观霉素的开发
- 批准号:
8860114 - 财政年份:2014
- 资助金额:
$ 53.95万 - 项目类别:
Development of Aminospectinomycins for Biodefense
用于生物防御的氨基大观霉素的开发
- 批准号:
8693411 - 财政年份:2014
- 资助金额:
$ 53.95万 - 项目类别:
Development of novel proteins synthesis inhibitors for MDR tuberculosis
耐多药结核病新型蛋白质合成抑制剂的开发
- 批准号:
7989056 - 财政年份:2010
- 资助金额:
$ 53.95万 - 项目类别:
相似国自然基金
两种溶血磷脂酸酰基转移酶参与大豆花叶病毒复制与宿主抗性的机制研究
- 批准号:32370158
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
灵芝中灵芝酸生物合成关键酰基转移酶的鉴定和功能研究
- 批准号:32360014
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
酰基转移酶选择性催化酯化虾青素合成的分子机制研究
- 批准号:32372283
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于串级质谱的磷脂酰胆碱酰基转移酶对底物异构体的选择性研究
- 批准号:22304088
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
二酰基甘油O-酰基转移酶1调控自噬流影响前列腺癌生长的作用及机制研究
- 批准号:
- 批准年份:2022
- 资助金额:51 万元
- 项目类别:面上项目
相似海外基金
Structure and Function of the LPLA2/LCAT Acyltransferase Family
LPLA2/LCAT 酰基转移酶家族的结构和功能
- 批准号:
8817382 - 财政年份:2014
- 资助金额:
$ 53.95万 - 项目类别:
Structure and Function of the LPLA2/LCAT Acyltransferase Family
LPLA2/LCAT 酰基转移酶家族的结构和功能
- 批准号:
9174909 - 财政年份:2014
- 资助金额:
$ 53.95万 - 项目类别:
Transformed Probiotic Bacteria for Treatment of Chronic Diseases
用于治疗慢性疾病的转化益生菌
- 批准号:
7431222 - 财政年份:2007
- 资助金额:
$ 53.95万 - 项目类别: